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ABSTRACT 
Several analogs of the cytotoxic thiopeptide IB-01211 or Mechercharmycin A (1) have 
been synthetized.  The cytotoxicity of 1 and the synthetized analogs was evaluated 
against a panel of three human tumor cell lines. Thiopeptide 1 and the most active 
derivatives, 2 and 3c, were chosen for further studies like effects on cell cycle 
progression and induction of apoptosis. Interestingly, the inhibition of cell division and 
activation of a programmed cell death by apoptosis was detected. 
 
Key words: azoles, peptides, conjugation, cytotoxicity  
INTRODUCTION 
Natural products are a rich source for drug discovery and are challenging synthetic 
targets; hence, they often inspire new synthetic methods.1 Thiazoles and oxazoles, as well 
as their reduced variants, are common structural features of many biologically important 
natural products.2 Only few concatenated azoles containing substituents on the azole 
rings have been described. These comprise the methylated bisoxazoles (-)-muscoride A3 
and leucamide A,4 the cyclic octa-azole telomestatin,5 which features two oxazole rings 
with methyl substituents at position 5 and finally, the diazonamides,6 which have a 
complex structure containing a bis-oxazole. IB-01211 or mechercharmycin A (1) is a 
cyclic thiopeptide7 containing a phenyl-penta-azole system, a D-allo-Ile-L-Val dipeptide, 
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and an exocyclic methylidene. The synthesis of 1 was recently described by our group.8 
Thiopeptide 1 is closely related in structure to the potent telomerase inhibitor 
telomestatin5 and YM-216391.9 
We sought to prepare analogs of 1with improved solubility and activity. The first 
structural modifications comprised substitution on the penta-azole system and 
modifications of the exocyclic methylidene (Figure 1). We envisaged that introduction of 
one (1a, b) or two (1c) methyl groups could increase the solubility of the parent 
compound and allow a conformational change. The second variation consisted of 
modifying the exocyclic double bond via elimination (2) or conjugation of the hydrate 
form 3 with acids, PEG residues or amino acids (3a-f).  
 
Figure 1. Structures of thiopeptide 1 and analogs 1a-c, 2 and 3a-f 
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RESULTS AND DISCUSSION 
Chemistry 
Compounds 1a-c, 2, and 3a-f were synthesized using basically the same strategy that we 
described for the total synthesis of 1.8a This is a convergent method based on 
macrocyclization with simultaneous formation of the thiazole ring from a peptide-
heterocycle. Having previously reported the difficulty of handling the alcohol 3,8 we used 
different conditions for the macrocyclization of the intermediates leading to 2 and the 
esters 3a-e than for those leading to 1a-c, which feature an exocyclic methylidene. Thus, 
whereas 3a-e were all prepared from 3 via experimental conditions that avoid 
dehydration, 1a-c were obtained through concomitant macrocyclization and formation of 
the thiazole and the double bond. 
The syntheses were built around three synthetic intermediates: the bis-oxazoles 4a-c, the 
phenyl-bis-oxazoles 5a and 5b, and the dipeptide 6 (Scheme 1). Compounds 4a and 5a 
have previously been synthesized8 by a process based on cyclization of Ser and Ph-Ser 
peptides to give an oxazoline, followed by further oxidation to afford the oxazole. This 
method was used to prepare oxazoles 4b, 4c and 5b, using Gly- and Thr-containing 
peptides, as well as Ser and Ph-Ser, as starting materials (see Experimental Details). The 
peptide-heterocycles 7a and 7b were obtained in excellent yields from the peptide 6 and 
compounds 5a, 5b, respectively, using EDC.HCl (1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride) and HOBt (1-hydroxybenzotriazole) as coupling 
agents. The tetra-oxazole-peptides 9 were obtained from the corresponding free acid of 
710 and the appropriate amine 8 under the conditions described above. Compounds 9a-e 
feature three key functional groups: a thioamide, an acetal-protected -bromoketone, and 
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a tert-butoxymethyl group (R = CH2OtBu for 9a-d). Simultaneous elimination of the 
OtBu protecting group and the dimethylacetal of 9 using formic acid under reflux 
afforded the free alcohol plus the -bromoketone, which was ready for macrocyclization 
via thiazole formation. Macrocyclization was achieved by refluxing a dilute ethanolic 
solution of the crude material for 48 h.11 For 1a-c (Scheme 1, left), this reaction was 
followed by dehydration of the crude material using mesyl chloride and triethyl amine 
(TEA) at low temperature. The last step after the macrocyclization was avoided when 9e 
was used to give compound 2. Using 9a this route gave, after deprotection and 
macrocyclization, alcohol 3, which was directly acylated to give 3a-e. Acetate 3a was 
obtained using acetic anhydride in THF at room temperature. Compounds 3b-e were 
prepared by reaction of the appropriate acid with the alcohol 3 using EDC.HCl and 4-
dimethylaminopyridine (DMAP) as condensation agents. The protection initially used for 
Arg was N-Boc, bis-N’-Alloc, which allowed isolation of 3d in 16% yield under the 
conditions described above. Elimination12 of the Alloc protecting group gave a crude 
product in which N-Boc-3f only corresponded to 3% (as detected by HPLC-MS). The 
deprotection gave better yield using tri-Boc-protected Arg. Simultaneous elimination of 
the three protecting groups of 3e using trifluoroacetic acid (TFA) diluted in CH2Cl2 
allowed the isolation with a 17% yield of purified 3f. 
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Scheme 1 Synthesis of thiopeptide 1 analogs 
 
 
BIOLOGICAL RESULTS 
The cytotoxicity of the thiopeptide 1 analogs was evaluated against a panel of three 
human tumor cell lines: A-549 lung carcinoma NSCL, HT-29 colon carcinoma, and 
MDA-MB-231 breast adenocarcinoma. 
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A conventional colorimetric assay was used to estimate values of GI50 (defined here as 
the drug concentration which causes 50% of cell growth inhibition after 72 hours of 
continuous exposure to the test molecule). Thiopeptide 1 was included for comparison. 
The results are shown in Table 1. 
Table 1 In vitro cytotoxicity of 1 and its open-chain and cyclic peptide analogs  
Compound 
Cytotoxicity (GI50 M) 
A-549 HT-29 MDA-MB-231 
1   0.03  0.04 0.09 
1a  1.66  2.49 2.91 
1b   0.54  0.63 1.02 
1c   0.31  0.36 0.70 
2  0.17  0.12 0.10 
3a  4.68 4.94  4.03 
3b    0.89 1.31 1.16 
3c   0.12  0.13 0.13 
3f  n.a. n.a. n.a. 
9a  n.a. n.a. n.a. 
9b  n.a. n.a. n.a. 
9c  4.99  n.a. 4.46 
9d  n.a. n.a. n.a. 
9e  n.a. n.a. n.a. 
 n.a.: not active at 10 g/mL 
All the cyclic analogs, except 3f, are active against human tumor cell lines, but to a lesser 
extend compared to 1. Introduction of one or two methyl-substituents (1a-c) diminishes 
the GI50 by one order of magnitude for 1b (lines A-549 and HT-29) and 1c (all three 
lines), and by two orders of magnitude for 1a (all three lines) and 1b (MDA-MB-231). 
The greatest cytotoxicity is found in derivatives in which the exocyclic double bond was 
eliminated (2) or substituted by a PEG-carboxymethyl (3b and 3c). Acetate derivative 3a 
maintains a modest growth inhibition at M concentrations in the three lines; however, 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
 8
acylation with an Arg residue leads to total loss of activity. Interestingly, substitution of 
the acetyl residue by a methoxyethoxyacetyl in 3b increases cytotoxicity to A-549; 
likewise, the longer polyetheracetyl of 3c produces the same effect in all three tumor cell 
lines. Compound 2 is a demethylidene analog of 1 and also a constitutional isomer of 
YM-216391. Compound 2 and YM-216391 differ only in the position of the thiazole ring 
inside the penta-azole structure of the macrocycle.13 The open ring precursors 9a-e are 
generally inactive; only 9c is moderately active against two tumor cell lines at M 
concentrations. The azole analogs14 of 1 recently obtained by our group, which do not 
contain the central thiazole, were also inactive. These results demonstrate the importance 
of the thiazole for the activity of these macrocyclic compounds.  
Thiopeptide 1 and the most active analogs 2 and 3c were then selected for further 
biological evaluation. 
Effects of 1, 2 and 3c on cell cycle progression of HT-29, A-549 and MDA-MB-231 
cells 
Thiopeptide 1 is closely related in structure to potent telomerase inhibitors such as 
telomestatin. Telomerase generates telomere repeats, specialized structures located at the 
end of eukaryotic chromosomes. Telomeres are important for maintenance of genomic 
stability and integrity during cell proliferation. Thiopeptide 1 and their analogs 2 and 3c 
were tested for effects on cell cycle progression in HT-29, A-549 and MDA-MB-231 
tumor cells. The cells were treated with each compound (see Material and Methods), and 
then analyzed by flow cytometry to determine if the cell cycle had been arrested at a 
specific phase. A control set of untreated cells was also used.  
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Compared to the control cells (Figure 2, panels 1a-c), the cells treated with 1 (Figure 2, 
panels 2a-c) and with compound 2 (Figure 2, panels 3a-c) had higher population stopped 
at the G2 phase, except A-549 cells treated with compound 2 that showed enlarged arrest 
in S phase. Nervertheless, cells treated with compound 3c showed a very pronounced 
arrest in S phase in all cell lines (Figure 2, panels 4a-c). Hence, these compounds alter 
cell cycle progression.  
Figure 2 Cell cycle progression in cancer cell lines treated with either 1, 2 or 3c 
 
Phase of 
Cell Cycle 
HT-29 A-549 MDA-MB-231 
a-1 a-2 a-3 a-4 b-1 b-2 b-3 b-4 c-1 c-2 c-3 c-4 
G1 (%) 45.5 51.3 39.7 27.2 66.3 55.5 50.4  40.0 60.9 46.4 50.3 33.6 
G2/M(%) 12.9 22.4 27.2  31.4 13.0 22.8 14.2 16.7 7.5 31.3 21.8 17.3 
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S (%) 41.4 26.2 33.0  41.2 20.6 21.6 35.3 43.1 31.5 22.2 27.8 49.0 
a-1: HT-29 asynchronous colon cell line; a-2: HT-29 with thiopeptide 1; a-3: HT-29 with compound 2; a-4: 
HT-29 with compound 3c; b-1: A-549 asynchronous lung cell line; b-2: A-549 with thiopeptide 1; b-3: A-
549 with compound 2; b-4: A-549 with compound 3c; c-1: MDA-MB-231 asynchronous breast cell line; c-
2: MDA-MB-231 with  thiopeptide 1; c-3: MDA-MB-231 with compound 2; c-4: MDA-MB-231 with 
compound 3c. 
 
 
 
 
 
 
Induction of apoptosis by either thiopeptide 1, 2 or 3c in HT-29, A-549 and MDA-MB-
231 cell lines 
Many anticancer drugs induce cell cycle arrest and apoptosis. Apoptotic cells undergo 
characteristic morphological changes. Among these, the cell surface often bends and 
breaks up into membrane-enclosed fragments called apoptotic bodies. This process 
depends on a cascade of proteolytic enzymes called caspases.15 They exist in most of the 
cells as inactive precursors (zymogens) that, once activated, kill cells.  
To analyze whether 1, 2 and 3c induce apoptosis, HT-29, A-549, MDA-MB-231 cell 
lines were incubated with each compound and then qualitatively measured for apoptosis 
(see Experimental Section). The analysis consisted of detecting active caspases (caspase-
3/7) using a colorimetric test (CaspaTag In situ Caspase Detection Kits, CHEMICON).  
All cell lines showed a high level of apoptotic cell death after treatment with either 1 
(Figure 3, panels 2a-c), compound 2 (Figure 3, panels 3a-c) and compound 3c (Figure 3, 
panels 4a-c). A negative control of the assay was performed by analyzing untreated cells 
under the same experimental conditions (Figure 3, panels 1a-c). 
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Figure 3 Analysis of apoptotic cell death in cancer cells treated with either 
thiopeptide 1, 2 or 3c 
 
a-1: HT-29 colon cell line negative control; a-2: HT-29 with compound thiopeptide 1; a-
3: HT-29 with compound 2; a-4: HT-29 with compound 3c; b-1: A-549 lung cell line 
negative control; b-2: A-549 with compound thiopeptide 1; b-3: A-549 with compound 2; 
b-4: A-549 with compound 3c; c-1: MDA-MB-231 breast cell line negative control; c-2: 
MDA-MB-231 with compound thiopeptide 1; c-3: MDA-MB-231 with compound 2; c-4: 
MDA-MB-231 with compound 3c. 
CONCLUSION 
Several analogs of thiopeptide 1 were synthesized using slight variations of a 
methodology previously described for the preparation of the parent compound. 
Conditions that allow isolation of the hydroxymethyl derivative have been established, 
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thus enabling preparation of several analogs by acylation. Methyl substituents were 
introduced onto the penta-azole system by employing different starting materials, 
whereas the exocyclic double bond was modified in the last synthetic step. 
Thiopeptide 1, and analogs 2 and 3c were shown to inhibit cell cycle progression in 
cancer cell lines. As previously mentioned, 1 is closely related in structure to YM-
2163919 and the potent telomerase inhibitor telomestatin.5  
Telomerase activity is important during telomere replication in chromosomes, thus 
telomerase inhibition will cause replication faults and DNA damage effect, which would 
in turn affect cell cycle progression. We observed that 1 and compound 2 caused cells to 
accumulate mainly in G2 phase, which could activate the G2-checkpoint activation. In 
contrast, 3c, by though less active than 1, provoked major S phase arrest in all cell lines, 
indicating that it has potent biological activity related to DNA replication. Moreover, the 
effects observed consecutively to the treatment of cells with 3c resemble those expected 
for a telomerase inhibitor.  
Perturbation of the cell cycle induces activation of apoptosis and leads to cell cycle arrest. 
Different cancer cell lines treated with either 1, 2 and 3c specifically underwent 
apoptosis, thereby indicating that these compounds do not act by some general toxicity 
mechanism. These compounds inhibit cell division and activate programmed cell death 
by apoptosis.  
The resemblance among 1, its analogs 2, 3c and known telomerase inhibitors, together 
with the fact that the majority of human tumors seem to depend on telomerase 
reactivation to prevent critical telomere loss, are testament to the potential of exploring 
these compounds as anticancer therapies. 
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EXPERIMENTAL SECTION  
General data see the supporting information.  
Compounds 4a, 5a, 6, 7a, 8a and 9a were synthesized as previously reported.8 
Macrocyclization-Elimination reaction for preparation of 1a-c 
A solution of 9 (1.0 mmol) in 98% HCO2H (28 mL) was stirred under reflux for 1 h. The 
reaction mixture was cooled, poured into a solution of NaHCO3, and then extracted with 
CH2Cl2. The organic layer was dried, and then concentrated in vacuo to give the keto- 
and O-deprotected product as a yellow oil. A solution of this oil in EtOH (70 mL) was 
stirred at 85 ºC for 48 h. Concentration in vacuo gave a brown residue, which was 
purified on the Isco Flash system with a RediSep silica gel disposable flash column. 
Elution with CH2Cl2_MeOH (9:1) gave the O-deprotected product as a yellow oil. This 
product was dissolved in dry CH2Cl2 (20 mL), and the solution was cooled to 0 ºC. TEA 
(2.48 mmol) and MsCl (1.24 mmol) were then added dropwise. The resulting solution 
was stirred for 5 h at 0 ºC, washed with NH4Cl and water, dried, and concentrated.  
Peptide-heterocycle (1a) The final product was purified by preparative HPLC using H2O 
(0.045% TFA) and MeCN (0.036% TFA) as eluents (gradient: 40% to 80% in 25 min; 
flow rate: 3 mL/min) to afford 1a (65.4 mg, 10%) as a yellow solid. m.p. (CHCl3) 165-
167 ºC. []D +16.8 (c 0.25, DMF). 1H NMR (DMF, 400 MHz)  0.81-1.07 (m, 12H); 
1.22-1.32 (m, 1H); 1.52-1.69 (m, 1H); 1.92-2.02 (m, 1H); 2.04-2.15 (m, 1H); 2.77 (s, 
3H); 4.42 (dd, J = 6.8 and 9.6 Hz, 1H); 4.79-4.82 (m, 1H); 5.69 (s, 1H); 6.19 (s, 1H); 
7.50-7.61 (m, 3H); 8.50-8.53 (m, 2H); 8.59 (s, 1H); 8.64 (bs, 1H); 8.91 (bs, 1H); 9.16 (s, 
1H); 9.19 (s, 1H); 10.22 (bs, 1H). 13C NMR (DMF, 100 MHz)  11.4 (q); 11.7 (q); 13.6 
(q); 18.7 (q); 19.3 (q); 26.7 (t); 31.8 (d); 39.7 (d); 55.6 (d); 60.6 (d); 104.5 (t); 121.3 (d); 
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127.0 (s); 127.9 (2d); 128.0 (s); 128.2 (s); 128.6 (2d); 129.3 (s); 130.2 (d); 130.7 (s); 
136.0 (s); 138.1 (s); 139.5 (d); 140.4 (d); 143.0 (s); 151.5 (s); 153.6 (s); 155.5 (s); 155.8 
(s); 156.5 (s); 157.5 (s); 157.9 (s); 171.0 (s); 172.2 (s). MS (MALDI-TOF) m/z 761 (M + 
K, 100), 745 (M + Na, 85). HRMS m/z calcd. for C36H38N9O7S (M + NH4) 740.2609 
found 740.2602.  
Peptide-heterocycle (1b) The final product was purified by preparative HPLC using H2O 
(0.045% TFA) and MeCN (0.036% TFA) as eluents (gradient: 40 to 80 in 25 min; flow 
3mL/min) to afford 1b (51.1 mg, 7%) as a yellow solid m.p. (CHCl3) 160-162 ºC. []D 
+18.4 (c 0.19, DMF). 1H NMR (DMF, 400 MHz)  0.81-1.01 (m, 12H); 1.21-1.33 (m, 
1H); 1.48-1.61 (m, 1H); 1.95-2.03 (m, 1H); 2.06-2.16 (m, 1H); 2.94 (s, 3H); 4.41 (dd, J = 
6.4 and 9.4 Hz, 1H); 4.81-4.84 (m, 1H); 5.77 (s, 1H); 6.22 (s, 1H); 7.49-7.62 (m, 3H); 
8.51 (s, 1H); 8.54-8.56 (m, 2H); 8.64 (bs, 1H); 8.90 (bs, 1H); 9.0 (s, 1H); 9.14 (s, 1H); 
10.30 (bs, 1H). 13C NMR (DMF, 100 MHz)  11.2 (q); 11.7 (q); 13.6 (q); 18.7 (q); 19.3 
(q); 26.7 (t); 31.7 (d); 39.8 (d); 55.6 (d); 60.7 (d); 105.4 (t); 125.6 (d); 127.2 (s); 127.8 
(2d); 128.1 (s); 128.5 (s); 128.7 (2d); 129.3 (s); 130.1 (d); 132.4 (s); 135.4 (s); 136.5 (s); 
139.5 (d); 140.7 (d); 143.6 (s); 151.4 (s); 153.3 (s); 156.2 (s); 158.4 (s); 159.0 (s); 159.6 
(s); 160.3 (s); 171.1 (s); 172.3 (s). MS (MALDI-TOF) m/z 761 (M + K, 100), 745 (M + 
Na, 85), HRMS m/z calcd. for C36H38N9O7S (M + NH4) 740.2609 found 740.2585.  
Peptide-heterocycle (1c) The final product was purified by preparative HPLC using H2O 
(0.045% TFA) and MeCN (0.036% TFA) as eluents (gradient: 50% to 90% in 25 min; 
flow rate: 3 mL/min) to afford 1c (75 mg, 8%) as a yellow solid m.p. (CHCl3) 155-157 
ºC. []D +18.6 (c 0.16, DMF). 1H NMR (DMF, 500 MHz)  0.81-1.08 (m, 12H); 1.20-
1.33 (m, 1H); 1.47-1.59 (m, 1H); 1.95-2.02 (m, 1H); 2.08-2.16 (m, 1H); 2.79 (s, 3H); 
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2.95 (s, 3H); 4.42 (dd, J = 5.6 and 11.4 Hz, 1H); 4.82 (m, 1H); 5.70 (s, 1H); 6.19 (s, 1H); 
7.53-7.61 (m, 3H); 8.51 (s, 1H); 8.56-8.57 (m, 2H); 8.63 (bs, 1H); 8.93 (bs, 1H); 9.16 (s, 
1H); 10.26 (bs, 1H). 13C NMR (DMF, 125 MHz)  11.6 (q); 11.9 (q); 12.1 (q); 14.3 (q); 
14.5 (q); 19.8 (q); 28.9 (t); 31.3 (d); 38.6 (d); 58.0 (d); 61.0 (d); 103.3 (t); 124.9 (d); 
128.7 (2d); 129.6 (2d); 130.8 (d); 138.6 (d). MS (MALDI-TOF) m/z 775 (M + K, 100), 
759 (M + Na, 85). HRMS m/z calcd. for C37H40N9O7S (M + NH4) 754.2765 found 
754.2764.  
Peptide-heterocycle (2) A solution of 9e (0.85 g, 1.01 mmol) in 98% HCO2H (25 mL) 
was refluxed for 1 h. The cool reaction mixture was poured into a solution of NaHCO3 
and extracted with CH2Cl2. The organic layer was dried, and concentrated in vacuo to 
give the keto-deprotected product as a yellow oil. A solution of the oil in ethanol (80 mL) 
was stirred at 85 ºC for 48 h. Concentration in vacuo gave a brown residue, which was 
purified by chromatography on silica gel. Elution with CH2Cl2-MeOH (100 to 95:5) and 
final purification was achieved by Isco Flash (4.3 gram Reverse Phase C18 RediSep 
column); H2O (0.04% TFA) and MeCN (0.04% TFA) as eluents (gradient: 5% to 20% in 
40 min; flow rate: 13 mL/min) to afford 2 (73 mg, 11%) as a yellow solid. m.p. (CHCl3) 
185-187 ºC. []D +40.1 (c 3.13, DMSO). 1H NMR (DMSO, 400 MHz)  0.85-0.92 (m, 
9H); 0.98 (d, J = 6.8 Hz, 3H); 1.03-1.10 (m, 2H); 1.58-1.64 (m, 1H); 2.02-2.15 (m, 1H); 
4.19-4.24 (m, 1H); 4.44-4.50 (m, 1H); 4.69-4.74 (m, 1H); 4.98 (dd, J = 9.2 and 16.8 Hz, 
1H); 7.51-7.58 (m, 4H); 8.33 (d, J = 7.2 Hz, 2H); 8.40 (d, J = 7.2 Hz, 1H); 8.52 (s, 1H); 
8.67 (d, J = 8.8 Hz, 1H); 8.8 (s, 1H); 9.05 (s, 1H); 9.12 (s, 1H). 13C NMR (DMSO, 100 
MHz)  11.8 (q); 14.5 (q); 17.5 (q); 19.6 (q); 25.4 (t); 31.1 (d); 55.2 (d); 57.0 (d); 57.5 
(d); 69.5 (t); 121.2 (d); 126.4 (s); 127.2 (d); 127.5 (s); 128.4 (2d); 129.1 (s); 129.4 (s); 
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129.9 (2d); 135.4 (s); 139.0 (d); 139.5 (d); 140.1 (s); 141.2 (d); 150.5 (s); 152.0 (s); 154.9 
(s); 157.3 (s); 159.8 (s); 162.6 (s); 170.0 (s); 170.2 (s); 170.6 (s). MS (ES) m/z 714 (M + 
NH4, 100), 316 (5), 288 (18). HRMS m/z calcd. for C34H33N8O7S 697.2187 (M + H) 
found 697.2187 
Macrocyclization-Acylation for preparation of 3a-d 
A solution of 9 (0.72 mmol) in 98% HCO2H (20 mL) was stirred under reflux 1 h. The 
reaction mixture was cooled, poured into a solution of NaHCO3, and then extracted with 
CH2Cl2. The organic layer was dried, and concentrated to give the keto- and O-
deprotected product as a yellow oil. A solution of the oil in EtOH (40 mL) was stirred at 
85 ºC for 48 h. Concentration in vacuo gave a brown residue, which, upon elution with 
CH2Cl2-MeOH (9:1), gave the alcohol 3 as a yellow oil. 
Peptide-heterocycle (3a) The alcohol 3 (105 mg, 0.14 mmol) was dissolved in dry THF 
(20 mL). Ac2O (0.45 mL, 4.82 mmol) was then added dropwise. The resulting solution 
was stirred for 8 h at room temperature, washed with NaHCO3, dried, and concentrated. 
The final product was purified by preparative HPLC using H2O (0.04% TFA) and MeCN 
(0.04% TFA) as eluents (gradient: 20% to 40% in 50 min; flow rate: 15 mL/min) to 
afford 3a (15 mg, 13%) as a yellow solid m.p. (CHCl3) 171-173 ºC. []D +71.8 (c 0.47, 
CHCl3). 1H NMR (CDCl3, 400 MHz)  0.93-1.01 (m, 12H); 1.28-1.35 (m, 2H); 1.63-1.75 
(m, 1H); 1.85-1.95 (m, 1H); 2.04 (s, 3H); 3.59-3.68 (m, 1H); 4.32-4.49 (m, 1H); 4.65-
4.75 (m, 2H); 5.75-5.84 (m, 1H); 6.15-6.24 (bs, 1H); 7.42-7.53 (m, 4H); 7.95 (s, 1H); 
8.19 (s, 1H); 8.26 (s, 2H); 8.36 (d, J = 7.2 Hz, 2H); 8.55 (bs, 1H). 13C NMR (CDCl3, 100 
MHz)  11.8 (q); 14.5 (q); 18.8 (q); 18.9 (q); 20.4 (q); 25.7 (d); 29.6 (t); 30.1 (d); 39.7 
(d); 47.0 (d); 56.5 (d); 63.6 (t); 119.6 (d); 126.5 (s); 127.2 (s); 128.0 (d); 128.5 (2d); 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
 17
129.4 (s); 130.0 (s); 130.2 (s); 130.3 (2d); 135.7 (d); 137.4 (s); 137.7 (d); 139.8 (d); 141.8 
(s); 151.4 (s); 153.0 (s); 156.0 (s); 158.2 (s); 160.4 (s); 162.4 (s); 170.8 (s); 171.7 (s); 
172.0 (s). MS (ES) m/z 786 (M + NH4, 100), 744 (12), 316 (12), 288 (38), 241 (12). 
HRMS m/z calcd. for C37H37N8O9S 769.2399 (M + H) found 769.2409.  
Peptide-heterocycle (3b) The alcohol 3 (87 mg, 0.12 mmol) was dissolved in dry 
CH2Cl2 (10 mL). 2-(2-methoxyethoxy) acetic acid (0.156 mL, 1.37 mmol), EDC.HCl 
(263 mg, 1.37 mmol) and DMAP (25 mg, 0.21 mmol) were then added. The resulting 
solution was stirred for 8 h at room temperature, washed with NaHCO3, dried and 
concentrated. The final product was purified by preparative HPLC using H2O (0.04% 
TFA) and MeCN (0.04% TFA) as eluents (gradient: 20% to 38% in 70 min; flow rate: 15 
mL/min) to afford 3b (13 mg, 13%) as a yellow solid m.p. (CHCl3) 145-147 ºC. []D –
30.2 (c 0.61, CHCl3). 1H NMR (CDCl3, 400 MHz)  0.84-1.07 (m, 12H); 1.26-1.35 (m, 
2H); 1.52-1.75 (m, 1H); 1.81-1.96 (m, 1H); 3.34 (s, 3H); 3.53-3.71 (m, 6H); 4.09-4.22 
(m, 2H); 4.46-4.56 (m, 1H); 4.59-4.81 (m, 1H); 5.55 (bs, 1H); 5.73-5.80 (m, 1H); 7.41-
7.51 (m, 4H); 7.94 (s, 1H); 8.20 (s, 1H); 8.24 (s, 1H); 8.27 (s, 1H); 8.34 (d, J = 8.0 Hz, 
2H); 8.57 (bs, 1H). 13C NMR (CDCl3, 100 MHz)  11.8 (q); 14.2 (q); 18.7 (q); 18.8 (q); 
25.8 (d); 29.6 (t); 39.6 (d); 46.7 (d); 56.3 (d); 58.8 (q); 59.7 (d); 67.9 (t); 69.9 (t); 70.5 (t); 
71.6 (t); 119.6 (d); 126.5 (s); 127.9 (s); 128.4 (d); 128.5 (2d); 129.9 (s); 130.3 (s); 130.3 
(s); 130.4 (2d); 135.7 (s); 137.5 (d); 137.7 (d); 139.7 (d); 139.9 (s); 141.8 (s); 151.3 (s); 
152.9 (s); 158.0 (s); 158.3 (s); 160.4 (s); 170.3 (s); 171.8 (s); 172.0 (s). MS (ES) m/z 860 
(M + NH4, 100), 744 (55), 726 (45), 316 (45), 288 (98), 242 (22). HRMS m/z calcd. for 
C40H43N8O11S 843.2750 (M + H) found 843.6727.  
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Peptide-heterocycle (3c) The alcohol 3 (111 mg, 0.15 mmol) was dissolved in dry 
CH2Cl2 (10 mL). 2-[2-(2-methoxyethoxy)ethoxy]acetic acid (0.25 mL, 1.65 mmol), 
EDC.HCl (316 mg, 1.65 mmol) and DMAP (30 mg, 0.25 mmol) were then added 
dropwise. The resulting solution was stirred for 8 h at room temperature, washed with 
NaHCO3, dried and concentrated. The final product was purified by preparative HPLC 
using H2O (0.04% TFA) and MeCN (0.04% TFA) as eluents (gradient: 20% to 38% in 70 
min; flow rate: 15 mL/min) to afford 3c (16 mg, 12%) as a yellow solid m.p. (CHCl3) 
139-141 ºC. []D –63.4 (c 0.56, CHCl3).  1H NMR (DMF, 400 MHz)  0.93-0.98 (m, 
6H); 1.01 (d, J = 6.8 Hz, 3H); 1.07 (d, J = 6.8 Hz, 3H); 1.24-1.30 (m, 2H); 1.38 (d, J = 
6.4 Hz, 1H); 1.54-1.74 (m, 1H); 2.11-2.28 (m, 1H); 3.28 (s, 3H); 3.55-3.70 (m, 10H); 
4.08-4.20 (m, 2H); 4.70-4.79 (m, 2H); 5.82 (s, 1H); 6.17 (s, 1H); 7.49-7.61 (m, 3H); 8.44 
(d, J = 8.0 Hz, 2H); 8.59 (s, 1H); 8.98 (s, 1H); 9.14 (s, 1H); 9.17 (s, 1H); 10.03 (bs, 1H). 
13C NMR (DMF, 100 MHz)  11.8 (q); 14.5 (q); 18.9 (q); 19.2 (q); 26.8 (d); 29.4 (t); 32.4 
(d); 39.4 (d); 58.1 (d); 58.2 (q); 60.1 (d); 68.1 (t); 68.3 (t); 70.3 (t); 70.4 (t); 70.5 (t); 71.9 
(t); 121.6 (d); 127.3 (s); 127.9 (2d); 128.4 (s); 128.7 (s); 128.8 (2d); 129.4 (s); 130.3 (s); 
130.4 (d); 136.5 (s); 139.8 (d); 140.7 (d); 140.8 (d); 142.2 (s); 152.8 (s); 155.8 (s); 158.1 
(s); 158.5 (s); 159.6 (s); 160.7 (s); 171.0 (s); 171.6 (s); 171.9 (s). MS (ES) m/z 904 (M + 
NH4, 40), 726 (100), 316 (8), 288 (38). HRMS m/z calcd. for C42H47N8O12S 887.3029 (M 
+ H) found 887.3037. 
Peptide-heterocycle (3d) The alcohol 3 (50 mg, 0.068 mmol) was dissolved in dry 
CH2Cl2 (7 mL) and Boc-L-Arg-(Alloc)2-OH (120 mg, 0.27 mmol), EDC.HCl (52 mg, 
0.27 mmol), DMAP (7 mg, 0.57 mmol) was added drop-wise. The resulting solution was 
stirred for 31 h at room temperature, washed with NaHCO3 and NH4Cl, dried, and 
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concentrated. The final product was purified by flash chromatography on silica Bondesil 
C8 using H2O (0.04% TFA) and MeCN (0.04% TFA) as eluents (gradient: 0% to 50%) to 
afford 3d (15.9 mg, 16%) as a yellow solid. []D –11.6 (c 0.82, DMSO). 1H NMR 
(DMSO, 400 MHz)  0.82-0.94 (m, 9H); 0.99 (d, J = 6.8 Hz, 3H); 1.07-1.17 (m, 2H); 
1.25 (s, 9H); 1.35-1.37 (m, 2H); 1.57-1.64 (m, 2H); 1.73-1.78 (m, 1H); 2.01-2.11 (m, 
1H); 3.09-3.16 (m, 2H); 3.57-3.65 (m, 1H); 3.79-3.91 (m, 3H); 4.47-4.51 (m, 2H); 4.62-
4.70 (m, 3H); 4.75-4.79 (m, 1H); 5.12-5.40 (m, 4H); 5.87-5.99 (m, 2H); 7.08 (bs, 1H); 
7.17 (bs, 1H); 7.30 (bs, 1H); 7.48-7.59 (m, 3H); 8.30-8.33 (m, 2H); 8.51 (s, 1H); 8.53 (s, 
1H); 8.79 (bs, 1H); 8.98 (s, 1H); 9.11 (s, 1H); 9.12 (s, 1H); 9.98 (bs, 1H). 13C NMR 
(DMSO, 100 MHz)  12.3 (q); 14.2 (q); 17.9 (q); 18.5 (q); 19.0 (q); 22.4 (d); 26.9 (t); 
28.1 (t); 28.9 (t); 31.9 (d); 41.7 (t); 53.4 (2d); 56.9 (d); 58.1 (d); 65.1 (t); 67.0 (t); 69.7 (t); 
78.1 (s); 117.1 (s); 117.2 (t); 118.3 (t); 121.2 (d); 126.4 (s); 127.2 (s); 127.5 (s); 127.8 (s); 
128.6 (2d); 129.1 (s); 129.6 (2d); 129.7 (s); 130.7 (d); 131.8 (d); 133.5 (s); 133.6 (d); 
135.6 (s); 139.5 (d); 140.4 (d); 141.4 (d); 150.4 (s); 152.1 (s); 154.7 (s); 157.4 (s); 157.5 
(s); 158.9 (s); 160.0 (s); 170.2 (s); 170.7 (s); 170.9 (s); 173.8 (s). MS (MALDI-TOF) m/z 
1189 (M + K), 1173 (M + Na, 15), 1151 (M, 10). HRMS m/z calcd. for C54H63N12O15S 
1151.4295 (M + H) found 1151.4251.           
Peptide-heterocycle (3e) The O-deprotected product (74 mg, 0.101 mmol) was dissolved 
in dry CH2Cl2 (10 mL). Boc-L-Arg-(Boc)2-OH (193 mg, 0.41 mmol), EDC.HCl (78 mg, 
0.41 mmol), and DMAP (12.4 mg, 0.102 mmol) were then added drop-wise. The 
resulting solution was stirred for 15 h at room temperature, washed with NaHCO3 and 
NH4Cl, dried and concentrated. The final product was purified by flash chromatography 
on silica Bondesil C8 using H2O (0.04% TFA) and MeCN (0.04% TFA) as eluents 
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(gradient: 0% to 50%) to give 3e (19 mg, 17%) as a white solid. []D –19.4 (c 0.12, 
DMSO). 1H NMR (DMSO, 400 MHz)  0.83-0.95 (m, 12H); 1.09-1.18 (m, 2H); 1.23 (s, 
9H); 1.36 (s, 9H); 1.43 (s, 9H); 1.45-1.52 (m, 4H); 1.60-1.68 (m, 1H); 1.96-2.03 (m, 1H); 
3.95-4.04 (m, 1H); 4.11-4.18 (m, 2H); 4.39-4.48 (m, 2H); 4.63-4.69 (m, 1H); 5.63-5.70 
(m, 1H); 7.14-7.28 (m, 2H); 7.50-7.75 (m, 3H); 8.17 (bs, 1H); 8.24 (bs, 1H); 8.39-8.41 
(m, 2H); 8.55 (s, 1H); 8.72 (bs, 1H); 8.96 (s, 1H); 9.09 (s, 1H); 9.14 (s, 1H); 10.7 (bs, 
1H). 13C NMR (DMSO, 100 MHz)  12.4 (q); 14.5 (q); 19.5 (q); 18.4 (q); 24.6 (d); 28.0 
(q); 28.1 (t); 28.3 (t); 28.4 (q); 28.7 (q); 29.4 (t); 31.2 (d); 46.8 (d); 53.7 (d); 56.0 (d); 60.2 
(t); 64.6 (t); 122.4 (d); 128.4 (2d); 129.3 (2d); 131.0 (d); 140.2 (d); 141.1 (d); 141.4 (d). 
MS (ES) m/z 1185 (M + 2H, 60), 1184 (M + H, 100). HRMS m/z calcd. for 
C51H63N12O13S ( M – Boc) 1083.4352 found 1083.4351.  
Peptide-heterocycle (3f) A solution of 3e (5 mg, 4.2 mol) in TFA-CH2Cl2 (25:75, 1 
mL) was stirred at room temperature for 2 h. The TFA was removed, and the product was 
used without purification. []D –40.1 (c 0.23, DMSO). 1H NMR (DMSO, 500 MHz)  
0.83-0.98 (m, 12H); 1.07-1.18 (m, 2H); 1.41-1.76 (m, 5H); 2.03-2.08 (m, 1H); 3.57-3.64 
(m, 1H); 4.0-4.04 (m, 1H); 4.08-4.18 (m, 3H); 4.49-4.56 (m, 2H); 4.65-4.68 (m, 1H); 
5.69-5.73 (m, 1H); 7.51-7.62 (m, 7H); 8.20 (d, J = 5.0 Hz, 1H); 8.39-8.41 (m, 2H); 8.56 
(s, 1H); 8.71 (d, J = 8.0 Hz, 1H); 8.80 (d, J = 9.0 Hz, 1H); 8.99 (s, 1H); 9.10 (s, 1H); 9.14 
(s, 1H). 13C NMR (DMSO, 125 MHz)  12.5 (q); 14.4 (q); 19.5 (q); 19.7 (q); 25.0 (t); 
25.1 (t); 26.0 (t); 26.8 (d); 30.4 (d); 46.9 (d); 56.2 (d); 58.4 (d); 60.3 (t); 65.2 (t); 70.4 (d); 
122.3 (d); 128.4 (2d); 129.3 (2d); 131.0 (d); 139.6 (d); 140.9 (d); 141.0 (d). MS (ES) m/z 
883 (M, 100). HRMS m/z calcd. for C41H47N12O9S 883.3304 found 883.3317.  
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Peptide-heterocycle (9b) Reaction (20 h) of the free acid 7a (816 mg, 1.28 mmol) and 
8b (500 mg, 1.54 mmol) using the general procedure for amide formation gave 9b (1.14 
g, 94%) as a solid. An analytical sample was purified by column chromatography (4:1 to 
2:3 hexane-EtOAc) to afford 9b as a yellow solid, m.p. (CHCl3) 143-145 ºC. []D +1.4 (c 
0.42, CHCl3). 1H NMR (CDCl3, 400 MHz)  0.91-1.02 (m, 12H); 1.07 (s, 9H); 1.19-1.29 
(m, 1H); 1.48-1.58 (m, 1H); 2.07-2.15 (m, 1H); 2.20-2.27 (m, 1H); 2.58 (s, 3H); 3.37 (s, 
6H); 3.67-3.73 (m, 1H); 3.76-3.80 (m, 1H); 3.89 (s, 2H); 4.46-4.50 (m, 1H); 4.58-4.63 
(m, 1H); 5.24-5.37 (m, 1H); 6.70 (d, J = 8.4 Hz, 1H); 7.17 (bs, 1H); 7.38-7.46 (m, 4H); 
7.80 (d, J = 8.4 Hz, 1H); 8.24-8.30 (m, 2H); 8.36 (s, 1H); 8.37 (s, 1H); 8.47 (bs, 1H). 13C 
NMR (CDCl3, 100 MHz)  11.6 (q); 11.7 (q); 14.8 (q); 17.7 (q); 19.3 (q); 26.3 (t); 27.2 
(q); 30.9 (d); 31.7 (t); 37.2 (d); 48.4 (d); 50.2 (2q); 57.4 (d); 58.3 (d); 62.2 (t); 73.9 (s); 
99.3 (s); 124.3 (s); 126.5 (s); 128.3 (2d); 128.5 (2d); 129.6 (s); 130.2 (d); 140.0 (d); 141.2 
(s); 142.6 (s); 143.0 (d); 151.3 (s); 151.7 (s); 153.0 (s); 155.8 (s); 161.3 (s); 161.4 (s); 
161.6 (s); 170.9 (s); 171.2 (s); 188.3 (s). MS (MALDI-TOF) 965 (MBr81 + Na, 100), 963 
(MBr79 + Na, 85). HRMS m/z calcd. for C42H5479BrN8O10S 941.2861 and 943.2850 found 
941.2867 and 943.2853.  
Peptide-heterocycle (9c) Reaction (20 h) of the free acid 7b (1 g, 1.54 mmol) and the N-
deprotected 8a (573 mg, 1.84 mmol) using the general procedure for amide formation 
gave 9c (1.38 g, 95%) as a yellow solid. An analytical sample was purified by column 
chromatography (1:1 to 2:3 hexane-EtOAc) to give 9c as a yellow solid, m.p. (CHCl3) 
116-118 ºC. []D +2.3 (c 0.61, CHCl3). 1H NMR (CDCl3, 400 MHz)  0.88-0.98 (m, 9H); 
1.01 (d, J = 6.8 Hz, 3H); 1.06 (s, 9H); 1.18-1.31 (m, 1H); 1.46-1.61 (m, 1H); 2.05-2.16 
(m, 1H); 2.19-2.27 (m, 1H); 2.78 (s, 3H); 3.36 (s, 6H); 3.67-3.75 (m, 1H); 3.77-3.81 (m, 
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1H); 3.87 (s, 2H); 4.45-4.66 (m, 2H); 5.32-5.42 (m, 1H); 6.79-6.88 (m, 1H); 7.36-7.46 
(m, 3H); 7.78-7.89 (m, 2H); 8.07 (s, 1H); 8.12-8.17 (m, 1H); 8.24-8.29 (m, 2H); 8.36 (s, 
1H); 8.51 (bs, 1H). 13C NMR (CDCl3, 100 MHz)  11.6 (q); 12.1 (q); 14.7 (q); 17.7 (q); 
19.3 (q); 26.4 (t); 27.2 (q); 30.8 (d); 31.8 (t); 37.2 (d); 48.5 (d); 50.2 (2q); 57.4 (d); 58.3 
(d); 62.4 (t); 73.9 (s); 99.2 (s); 125.0 (s); 126.7 (s); 128.2 (2d); 128.3 (2d); 129.4 (s); 
130.0 (d); 139.4 (d); 141.4 (s); 143.3 (d); 152.0 (s); 152.4 (s); 152.8 (s); 154.6 (s); 158.8 
(s); 161.4 (s); 164.1 (s); 171.0 (s); 171.3 (s); 173.6 (s); 188.0 (s). MS (MALDI-TOF) 965 
(MBr81 + Na, 100), 963 (MBr79 + Na, 80). HRMS m/z calcd. for C42H5479BrN8O10S 
941.2861 found 941.2870.  
Peptide-heterocycle (9d) Reaction (20 h) of the free acid 7b (763 mg, 1.17 mmol) and 
8b (458 mg, 1.41 mmol) using the general procedure for amide formation gave 9d as a 
solid (1.05 g, 94%). An analytical sample was purified by column chromatography (4:1 
to 2:3 hexane-EtOAc) to give 9d as a yellow solid, m.p. (CHCl3) 147-149 ºC. []D +3.5 
(c 0.76, CHCl3). 1H NMR (CDCl3, 400 MHz)  0.91-1.03 (m, 12H); 1.09 (s, 9H); 1.22-
1.31 (m, 1H); 1.47-1.58 (m, 1H); 2.08-2.17 (m, 1H); 2.21-2.30 (m, 1H); 2.58 (s, 3H); 
2.79 (s, 3H); 3.37 (s, 6H); 3.68-3.73 (m, 1H); 3.77-3.80 (m, 1H); 3.88 (s, 2H); 4.43-4.54 
(m, 1H); 4.57-4.63 (m, 1H); 5.24-5.37 (m, 1H); 6.69 (d, J = 8.4 Hz, 1H); 7.10 (bs, 1H); 
7.38-7.46 (m, 3H); 7.78-7.83 (m, 2H); 8.25-8.30 (m, 2H); 8.37 (s, 1H); 8.44 (bs, 1H). 13C 
NMR (CDCl3, 100 MHz)  11.6 (q); 11.7 (q); 12.1 (q); 14.7 (q); 17.7 (q); 19.3 (q); 26.4 
(t); 27.3 (q); 30.9 (d); 31.8 (t); 37.1 (d); 48.4 (d); 50.3 (2q); 57.4 (d); 58.3 (d); 62.2 (t); 
73.9 (s); 99.2 (s); 124.4 (s); 125.0 (s); 126.7 (s); 128.3 (2d); 128.4 (2d); 129.4 (s); 130.0 
(d); 141.2 (s); 142.9 (d); 151.2 (s); 152.0 (s); 152.5 (s); 152.8 (s); 155.8 (s); 158.8 (s); 
161.5 (s); 170.8 (s); 171.0 (s); 171.2 (s); 188.4 (s). MS (MALDI-TOF) 979 (MBr81 + Na, 
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100), 977 (MBr79 + Na, 85). HRMS m/z calcd. for C43H5679BrN8O10S 955.3018 and to 
C43H5681BrN8O10S 957.3007 found 955.3028 and 957.3009.  
Peptide-heterocycle (9e) Reaction (20 h) of the free acid 7a (1.37 g, 2.15 mmol) and 8c 
(580 mg, 2.59 mmol) using the general procedure for amide formation gave 9e (1.78 g, 
98%) as a solid. An analytical sample was purified by column chromatography (1:1 to 2:3 
hexane-EtOAc) to give 9e as a solid m.p. (CHCl3) 132-134 ºC. []D +22.4 (c 0.49, 
CHCl3). 1H NMR (CDCl3, 400 MHz)  0.89-1.07 (m, 12H); 1.22-1.31 (m, 1H); 1.51-1.61 
(m, 1H); 2.05-2.18 (m, 1H); 2.21-2.45 (m, 1H); 3.37 (s, 6H); 3.79-3.86 (m, 1H); 3.89 (s, 
2H); 4.29-4.84 (m, 3H); 6.77-6.95 (m, 1H); 7.35-7.44 (m, 3H); 7.74-7.85 (m, 2H); 8.04 
(s, 1H); 8.09-8.12 (m, 1H); 8.17-8.25 (m, 2H); 8.31 (s, 1H); 8.36 (s, 1H); 8.49 (bs, 1H). 
13C NMR (CDCl3, 100 MHz)  11.3 (q); 15.0 (q); 17.5 (q); 19.5 (q); 26.0 (t); 29.8 (d); 
31.6 (t); 36.4 (t); 36.6 (d); 50.3 (2q); 58.4 (d); 58.6 (d); 99.3 (s); 126.5 (s); 128.2 (2d); 
128.4 (2d); 129.4 (s); 130.1 (s); 130.3 (d); 139.6 (d); 140.1 (d); 141.4 (s); 143.3 (d); 151.8 
(s); 153.0 (s); 154.5 (s); 161.4 (s); 161.7 (s); 161.9 (s); 162.6 (s); 171.5 (s); 171.8 (s); 
188.1 (s). MS (MALDI-TOF) 865 (MBr81 + Na, 100), 863 (MBr79 + Na, 85). HRMS m/z 
calcd. for C36H4279BrN8O9S 841.1973 found 841.1968.  
Cell lines and Culture 
Human-derived established cell lines used in this study were purchased from ATCC 
(American Type Culture Collection): A-549, human lung carcinoma (ATCC # CCL-185), 
HT-29, human colorectal adenocarcinoma (ATCC # HTB-38), and MDA-MB 231, 
human breast adenocarcinoma (ATCC # HTB-26). 
All cell lines are maintained in DMEM (Dulbecco's Modified Eagle's Medium) culture 
medium supplemented with 10% FBS (Fetal bovine serum), and 100 Units/mL penicillin 
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and streptomycin at 37 ºC and 5% CO2. Triplicate cultures were incubated for 72 hours in 
the presence or absence of test compounds (at 10 concentrations typically ranging from 
10 to 0.0026 g/mL). 
A colorimetric assay using sulforhodamine B (SRB) has been adapted for a quantitative 
measurement of cell growth and viability, following a previously described method.16 
Cells are plated in 96-well microtiter plates at a density of 5x103/well and incubated for 
24 hours. One plate from each different cell line is fixed and stained, and used for Tz 
reference (see next paragraph). After that, cells are treated with vehicle alone (control) or 
compounds at the concentrations indicated. Treated cells are further incubated for 72 
hours and cytotoxic evaluation performed by colorimetric analysis. 
In brief, cells are washed twice with phosphate buffered saline (PBS), fixed for 15 min in 
1% glutaraldehyde solution, rinsed twice in PBS, and stained in 0.4% SRB solution for 
30 min at room temperature. Cells are then rinsed several times in 1% acetic acid solution 
and air-dried. SRB was then extracted in 10 mM trizma base solution and the absorbance 
measured at 490 nm. Cell survival is expressed as percentage of control cell growth. 
Dose-response curves are performed by using the NCI algorithm:17 Tz= number of 
control cells at time t0, C= number of control cells at time t, and T= number of treated 
cells at time t. 
If Tz < T < C (Growth inhibition) then: 100*([T-Tz]/[C-Tz]) 
If T < Tz (Net cell killing) then: 100*([T-Tz]/Tz) 
After dose-curve generation, results are experessed as GI50, compound concentration that 
causes 50% cell growth inhibition, as compare to control cultures. 
Cell cycle analysis 
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Cell cycle analysis was performed by propidium iodide staining to determine DNA 
content. Subconfluent cells treated with either 35 nM 1 or 172 nM 2 or 135 nM 3c for 12 
h, were trypsinyzed, collected by centrifugation, resuspended in PBS, and then fixed in 
70% ethanol. The fixed cells were incubated with 5 mg/mL propidium iodide (Sigma), 
0.1 mg/mL RNase A (Sigma), and 0.1% triton X-100 for 15 min at 37 ºC and analyzed 
with a Beckman Coulter Epics XL using the 488 nm line of argon laser. The cell cycle 
profile was analyzed using Cell Quest software. 
Apoptosis assay 
The methodology used is based on fluorochrome inhibitors of caspases (FLICA; 
CaspaTag In situ Caspase Detection Kits, Chemicon International, USA and Canada). 
The inhibitors are cell permeable and non-cytotoxic. Once inside the cell, the inhibitor 
covalently binds to the active caspase. This kit uses a carboxyfluorescein-labeled 
fluoromethyl ketone peptide inhibitor of caspase-3 (FAM-DEVD-FMK), which 
fluoresces green. When added to a group of cells, the FAM-DEVD-FMK probe enters 
each cell and covalently binds to a reactive cysteine residue in the large subunit of the 
active caspase heterodimer, thereby inhibiting further enzymatic activity. 18  
Subconfluent cells cultured on coverslips were treated with either 35 nM 1 or 172 nM 2 
or 135 nM 3c for 24 h. After treatment, 30X FLICA reagent was added at 1:15 dilution in 
culture medium and incubated for 1 h at 37 ºC. The cells were washed with PBS and 
analyzed using a Leica TCS SP2 laser scanning confocal spectral microscope (Leica 
Microsystems Heidelberg GmbH, Mannheim, Germany) with a band pass filter excitation 
at 490 nm and emission at 520 nm to view the green fluorescence of caspase-positive 
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cells. The green fluorescence signal was a direct measure of the amount of active 
caspase-3/7 present in the cell at the time the reagent was added.  
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